Profil
Anette Sundstedt served as a Director at Active Biotech AB from 2001 to 2016.
She also held the position of Director at Alligator Bioscience AB from 2021 to 2024.
Dr. Sundstedt was the Chief Scientific Officer at Idogen AB. Additionally, she served as the Chief Development Officer at CanImGuide Therapeutics AB from 2020 to 2021.
Dr. Sundstedt obtained her graduate and doctorate degrees from the University of Lund.
Anciens postes connus de Anette Sundstedt
| Sociétés | Poste | Fin |
|---|---|---|
| ALLIGATOR BIOSCIENCE AB | Directeur/Membre du Conseil | 07/05/2024 |
CanImGuide Therapeutics AB
CanImGuide Therapeutics AB Pharmaceuticals: MajorHealth Technology Develops cancer therapies | Corporate Officer/Principal | 01/03/2021 |
| ACTIVE BIOTECH AB | Directeur/Membre du Conseil | 01/01/2016 |
Idogen AB
Idogen AB BiotechnologyHealth Technology Develops cell therapies for treatment of autoimmune diseases | Directeur Technique/Scientifique/R&D | - |
Formation de Anette Sundstedt
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
Active Biotech AB
Active Biotech AB BiotechnologyHealth Technology Develops drugs for cancer, neurodegenerative and inflammatory diseases | Health Technology |
Alligator Bioscience AB
Alligator Bioscience AB BiotechnologyHealth Technology Operates as a clinical stage biotechnology company that develops antibodies for the treatment of cancers | Health Technology |
University of Lund
University of Lund Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
CanImGuide Therapeutics AB
CanImGuide Therapeutics AB Pharmaceuticals: MajorHealth Technology Develops cancer therapies | Health Technology |
Idogen AB
Idogen AB BiotechnologyHealth Technology Develops cell therapies for treatment of autoimmune diseases | Health Technology |
















